Leading the way to safer medication
 Crosscheck  Recommender

Bortezomib

Description

Bortezomib is a proteasome inhibitor. It is specifically designed to inhibit the chymotrypsin-like activity of the 26S proteasome in mammalian cells. Inhibition of the 26S proteasome prevents this targeted proteolysis and affects multiple signalling cascades within the cell, ultimately resulting in cancer cell death.

ATC Classification

Code
Title
Category
L01XG01
Bortezomib
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XG Proteasome inhibitors

Trade names

Trade name
Countries

Singapore

Singapore

Singapore

Australia Austria Canada Cyprus Netherlands

Singapore

Product Monographs

Monograph
Type
Country
VELCADE Powder for solution
MPI, EU: SmPC